Laboratory and case-control studies suggest a pivotal role for the cyclooxygenase-2 (COX-2) pathway in colorectal carcinogenesis. The purpose of this study was to test whether the COX-2 inhibitor rofecoxib could reduce recurrence and improve survival when administered in the adjuvant setting of colorectal cancer (CRC).
INTRODUCTION
Approximately half of all patients undergoing potentially curative surgery for colorectal cancer (CRC) ultimately experience relapse and die of metastatic disease. This has led to the introduction of adjuvant chemotherapy, 1 the absolute overall survival (OS) benefits of which are stage dependent and relatively small (4% to 10% improvement in 5-year OS). [2] [3] [4] Cyclooxygenase-2 (COX-2) plays an important role in colorectal carcinogenesis during the transition from adenoma to carcinoma and in invasion, angiogenesis, and metastasis. [5] [6] [7] Immunohistochemical analysis of CRC tissue suggests that 70% of tumors express COX-2; this increases with stage progression and correlates with coexpression of the progression factors matrix metalloproteinase-2 and vascular endothelial growth factor. 8, 9 Haile et al 10 demonstrated that nonsteroidal anti-inflammatory drug-induced reduction in polyp recurrence was greater in adenomas with high levels of COX-2 expression. Similarly, Chan et al 11 found that aspirin use significantly reduced CRC risk in tumors overexpressing COX-2 (relative risk ϭ 0.64; 95% CI, 0.52 to 0.78) but not in cancers with weak or absent COX-2 expression (relative risk ϭ 0.96; 95% CI, 0.73 to 1.26). We hypothesized that rofecoxib [12] [13] [14] [15] [16] [17] [18] would provide a safe approach to blocking COX-2 and reduce the rate of tumor recurrence in patients who had undergone potentially curative surgery for CRC and that the level of tissue expression of the COX-2 enzyme in the tumor might modulate this effect. We have previously reported cardiovascular safety data from the Vioxx in Colorectal Cancer Therapy: Definition of Optimal Regime (VICTOR) trial 19 and now present efficacy analyses with comparisons of OS and disease-free survival (DFS) for rofecoxib versus placebo.
PATIENTS AND METHODS

Patients
Inclusion criteria included the following: histologically proven stage II and III CRC in patients who had complete resection of the primary tumor; WHO performance status of 0 or 1; and hematologic, liver, and renal function within the normal range. All patients had completed therapy (surgery Ϯ radiotherapy Ϯ chemotherapy) 12 or fewer weeks previously and had given written informed consent. Patients with peptic ulceration or GI bleeding in the past year; receiving long-term nonsteroidal anti-inflammatory drug therapy (except low-dose aspirin, Յ 100 mg/ d); younger than age 18 years; or with a history of cancer (other than treated in situ cervical carcinoma, basal cell carcinoma, or squamous cell carcinoma), inflammatory bowel disease, or severe congestive heart failure; women who were pregnant or lactating; and premenopausal women not using contraception were excluded. Patients who had stable angina, a myocardial infarction, or transient ischemic attack more than 6 months earlier were eligible.
Trial Design
Patients were randomly assigned in a double-blind fashion to rofecoxib or placebo by the VICTOR Trial Office, which supplied drugs to 151 hospitals in the United Kingdom every 6 months. Balance of prognostic variables was ensured by a sequential allocation procedure (minimization) using stage (II or III), disease site (colon, rectum, or rectosigmoid), age (Ͻ 50, 50 to 59, 60 to 69, or 70ϩ years), prior adjuvant chemotherapy, and radiotherapy.
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Protocol Modifications
Data collection forms were amended in January 2004 to solicit baseline data on cardiovascular risk factors for all patients. After withdrawal of rofecoxib in September 2004, all investigators and patients were informed, study treatment was stopped, and follow-up was continued at 3, 6, 12, 18, and 24 months after random assignment and annually thereafter. Patients received a colonoscopy between 1 and 2 years after primary surgery and every 3 years thereafter, a computed tomography scan 1 year after surgery, and clinical examination and routine blood tests at outpatient visits. All recurrences were confirmed by computed tomography or magnetic resonance imaging scan, and patients were flagged for survival with the United Kingdom's Office of National Statistics. Adverse event data were recorded systematically throughout the study and were reviewed by the trials team (R.S.M., D.J.K., and M.J.L.) to clarify diagnoses.
Assessment of COX-2 Expression
An a priori hypothesis was generated that COX-2 expression would correlate with response to rofecoxib. Immunohistochemical staining of tumors was performed for 871 patients on tissue microarrays that contained triplicate cores for each tumor specimen, using a rabbit polyclonal COX-2 antibody (1:1,000 dilution; Abcam, Cambridge, United Kingdom). COX-2 expression was evaluated independently by two researchers and was graded using a standardized grading system as absent (score ϭ 0), weak staining (score ϭ 1), moderate staining (score ϭ 2), or strong staining (score ϭ 3); the same criteria were used in the study by Chan et al. 11 The staining category of absent was used if COX-2 expression in the tumor was the same level of intensity as in the adjacent normal epithelium, with weak, moderate, and strong staining indicating increasing degrees of overexpression. The study pathologists in this case considered those tissues that were strongly stained (score ϭ 3) to be sufficiently distinct from the other categories to warrant separate categorization in the statistical analyses. Patients used in this biomarker study were similar to the main trial population with respect to age, sex, stage, site, and treatment.
Statistical Considerations
The original study aimed to recruit 7,000 patients and was powered to detect a reduction in risk of death between treatments for stage II and III separately (hazard ratio [HR] ϭ 0.80, with type I error of 0.05) at more than 85% power (two-sided test), assuming 60% of patients had stage III disease The modified statistical plan, after premature closure with 2,434 patients, aimed to detect a reduction in risk of death of HR ϭ 0.75 with 87% power and type I error of 0.05. OS, the primary end point, was measured from random assignment to death from any cause. Secondary end points include DFS, which was measured from random assignment to recurrence or death from any cause, and recurrence-free survival (RFS), which was measured from random assignment to recurrence and/or CRC death.
Kaplan-Meier curves and log-rank analysis were used for comparisons of OS, DFS, and RFS. Subgroups were examined using HR plots, and HR CIs were calculated from log-rank statistics and variances. 21 Cox proportional hazards models were used to estimate the treatment effect adjusted by prognostic factors. All reported P values are two-sided. All HRs are unadjusted unless otherwise specified. Graphical examination showed no clear departure from proportional hazards. For analysis of OS, patients not reported as dead were censored at their last known date alive. For analysis of DFS, patients who were alive and recurrence free were censored at their last known recurrence-free date. For analysis of RFS in first year after random assignment, patients who were alive and recurrence free at 1 year were censored at that time. Numbers of serious adverse events (SAEs) and sites of first recurrence were compared using a normal approximation to the Poisson distribution. All statistical analyses were carried out using the SAS version 9.2 statistical software (SAS Institute, Cary, NC).
Ethics and Indemnity
The protocol was peer reviewed by the Cancer Research Campaign, the Multicenter Research Ethics Committee, and research ethics committees at participating centers.
Role of the Funding Source
The trial was supported by an unrestricted grant from Merck (Whitehouse Station, NJ), which also provided rofecoxib, placebo, and indemnity but otherwise had no input into data accrual, analysis, or manuscript preparation.
RESULTS
Between April 2002 and September 2004, 2,434 patients were recruited at 151 hospitals in the United Kingdom. The intent-to-treat population used for outcome analysis comprised 1,217 patients randomly assigned to rofecoxib and 1,217 patients assigned to placebo. Fifty patients randomly assigned to rofecoxib and 57 patients randomly assigned to placebo had not yet started treatment when the drug was withdrawn. Therefore, the treated population comprised 1,167 rofecoxib-treated patients and 1,160 placebo-treated patients (Fig 1) .
Study treatment assignment was balanced based on sex, disease site, stage, age and prior adjuvant treatment ( Table 1 ). The median time on treatment was 7.4 months (interquartile range, 3.1 to 14.0 months) and 8.2 months (interquartile range, 3.7 to 14.9 months) for rofecoxib and placebo, respectively, with 33% of patients having completed at least 12 months of treatment. Eighteen patients randomly assigned to 2 years of rofecoxib and 23 patients randomly assigned to 2 years of placebo were reported as having completed their study treatment. Eight hundred six patients were still on rofecoxib and 862 patients were still on placebo when rofecoxib was withdrawn. The difference in the duration of treatment was related to a higher proportion of early discontinuations in the rofecoxib arm for adverse effects. The most common medical reasons for early drug withdrawal were GI pain or heartburn (15 patients on rofecoxib and five patients on placebo), analgesia required for arthritis (four on rofecoxib and 15 on placebo), hypertension (seven on rofecoxib and one on placebo), renal impairment (seven on rofecoxib and one on placebo), diarrhea (four on rofecoxib and four on placebo), and heart failure (two on rofecoxib).
Safety (Treated Population)
SAEs were collected for each patient from enrollment until the SAE data lock of November 2007 (Table 2) . Cardiovascular thrombotic events have been reported in detail elsewhere.
19 GI SAEs included indigestion/gastroduodenal ulceration, diarrhea, constipation, and obstruction as a result of probable adhesions, all of which were reported in less than 1% of patients with no significant difference in frequency comparing rofecoxib and placebo.
OS
Median follow-up time was 58.1 months (interquartile range, 48.1 to 62.0 months) for the rofecoxib group and 58.2 months (interquartile range, 47.8 to 61.9 months) for the placebo group. Over the study period, there were 241 deaths in the rofecoxib group and 246 in the placebo group. The HR for dying from any cause with rofecoxib compared with placebo was 0.97 (95% CI, 0.81 to 1.16; P ϭ .75). The HR for CRC-specific mortality was 0.98 (95% CI, 0.81 to 1.19; P ϭ .82). The 3-year Kaplan-Meier OS rates were 87.7% (95% CI, 85.7% to 89.4%) for the rofecoxib group and 86.9% (95% CI, 84.8% to 88.7%) for the placebo group (Fig 2) , with little evidence of variation according to known prognostic factors (stage, age, radiotherapy, and sex; Appendix Fig A1, online only) .
DFS and RFS
There were 335 DFS events in the rofecoxib group and 369 in the placebo group. The HR for disease recurrence or death from any cause with rofecoxib compared with placebo was 0.89 (95% CI, 0.77 to 1.04; P ϭ .14). In absolute terms, the 3-year DFS rates were 75.6% (95% CI, 73.0% to 78.0%) for the rofecoxib group and 73.4% (95% CI, 70.7% to 75.9%) for the placebo group. The HR for RFS with rofecoxib compared with placebo was 0.89 (95% CI, 0.76 to 1.04; P ϭ .15). There were 297 recurrences in the rofecoxib group and 329 in the placebo group, of which 110 and 141, respectively, were in the first year (P ϭ .044; Fig 3; Appendix Fig A2, online only) . Sites of recurrence were reported for 98% of patients on first recurrence. The total number of sites (each patient may have Ͼ one) was 433 in the rofecoxib group and 502 in the placebo group (P ϭ .02). The slight excess was not restricted to any particular site.
COX-2 Expression
Little evidence was found to suggest that the degree of COX-2 expression is associated with prognosis (low [score of 0 or 1] v moderate [score of 2] v high [score of 3]; HR for RFS ϭ 0.93; 95% CI, 0.78 to 1.12; P ϭ .45; Fig 4) . Although the RFS curves (Fig 5) comparing low-moderate COX-2 expressors (score of 0 to 2) versus high COX-2 expressors (score of 3) and the effect of rofecoxib treatment hint at a disproportionately beneficial effect of rofecoxib versus placebo in patients whose tumors had high expression of COX-2, statistically there is no treatment interaction (HR ϭ 0.75; 95% CI, 0.37 to 1.52; P ϭ .42) comparing these groups. However, possibility of statistical significance is hampered by the small number of events in this adjusted analysis (adjusted by stage, age, and radiotherapy group). 
DISCUSSION
We reasoned that blockade of COX-2 by rofecoxib would induce the following downstream events: direct inhibition of growth of residual micrometastases, prevention of angiogenesis, and reduction in tumoral expression of matrix metalloproteinases. Given the relative GI safety of rofecoxib, 14 we initially reasoned that a small (3%) absolute improvement in 5-year survival, if proven, would be sufficient to warrant use of this agent in the adjuvant setting. Results show no overall benefit for rofecoxib, with no improvements in DFS or OS. Although the trial recruited 2,434 patients, four potential reasons why a statistically significant benefit was not established are as follows: the drug is inactive; there were too few patients to demonstrate a clinically relevant but small effect; the duration of effective COX-2 inhibition may have been insufficient to alter the malignant phenotype; or there was inadequate representation of a COX-2-sensitive subpopulation. Data from the aspirin CRC prevention studies suggest a dose and duration effect for cancer risk reduction, 22 and the positive adenoma prevention studies with COX-2 inhibitors exposed patients to 16 to 36 months of drug treatment. 12, 15, 17 The premature closure of this trial and abbreviated duration of treatment may have attenuated therapeutic benefit. From previous adjuvant studies, it has been established that the greatest number of CRC recurrences occur in the first year after surgery 23 and the majority of adjuvant chemotherapy benefits are accrued then, with little demonstrable therapeutic effect in subsequent years. 2 In this study, there was a significant trend toward prevention of recurrence by rofecoxib in the first year (110 v 141 recurrences in the first year for rofecoxib and placebo, respectively; P ϭ .044), which could indicate that more prolonged exposure to rofecoxib would be beneficial.
There are prior data suggesting that tumoral expression of COX-2 is a poor prognostic feature, 24-26 although this was not observed in the current study. Edelman et al 24 demonstrated a survival benefit for a subgroup of patients with advanced nonsmall-cell lung cancer with increased COX-2 expression who received celecoxib, suggesting that COX-associated biomarkers might be used to select patients who could enjoy therapeutic benefit. However, in our study, despite the RFS curves hinting at a similar effect, statistically there was no evidence of a treatment interaction for rofecoxib relative to COX-2 expression.
In general, rofecoxib was well tolerated apart from the enhanced cardiovascular adverse event profile (1% to 2% of treated patients), 13,16,27,28 which could likely be avoided by better patient selection. The present study was compromised by the worldwide withdrawal of rofecoxib and, therefore, significant reduction in the duration of exposure for patients who were randomly assigned. However, there is still significant interest in the potential role of COX-2 inhibition in cancer secondary prevention, and a further trial of this family of drugs with careful patient selection, maintenance of exposure, and a careful parallel assessment of biomarkers is worthy of consideration. Indeed, a Cancer and Leukemia Group B/Southwest Oncology Group phase III trial that is about to open will test celecoxib in a 2 ϫ 2 factorial fashion with infusional fluorouracil, leucovorin, and oxaliplatin (3 months v 6 months of therapy) in the adjuvant setting of CRC. It will be extremely interesting to see whether the size of this study will allow confirmation of the provocative findings we describe here. 
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